Remove 2024 Remove Communication Remove Vaccines
article thumbnail

CureVac gets an early date in Covid-19 vaccine patent case with Pfizer/BioNTech

Pharmaceutical Technology

The ongoing patent litigation between CureVac and Pfizer /BioNTech will move to a court in Virginia following a request from Curevac, potentially bringing forward the trial date to sometime in 2024. The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly.

Vaccines 116
article thumbnail

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CDC Director Mandy Cohen unscathed in her first congressional testimony

STAT

They hope to gut a data program and slash HIV funds in the 2024 budget, but they also asked questions about the breadth of the agency’s portfolio outside of communicable diseases. Read the rest…

article thumbnail

State of Well-Being 2023-2024

The Happy PharmD

The strain on pharmacists can lead to errors, as evidenced by a pharmacist who almost administered the wrong vaccine dosage due to workload pressures. A cultural shift within the profession is also needed, encouraging open communication and prioritizing self-care to create a supportive environment for pharmacists.

article thumbnail

Novavax is on thin ice, and the latest update isn’t exactly encouraging

STAT

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 In 2024, as in 2023, the industry’s fate seems inextricable from interest rates. Novavax won’t disclose its revenue until later this month, but its latest communications don’t exactly inspire confidence.

Vaccines 129
article thumbnail

FDA gives Ferring go-ahead for Adstiladrin gene therapy manufacturing

Pharmaceutical Technology

The company aims to then increase supplies in 2024. Common treatment options for the condition include bladder removal surgery, chemotherapy and/or administration of the BCG vaccine in the bladder. Ferring plans to begin Adstiladrin production in the H2 2023, as part of an initial rollout in the US.

FDA 98
article thumbnail

Professor Klaus Meier on the collaborative future of oncology pharmacy

Hospital Pharmacy Europe

Developments such as mRNA cancer vaccines , pharmacogenomics and personalised medicine are going to be transformative for the sector, Professor Meier says. And he draws a parallel to the Covid-19 pandemic when pharmacists played a central role when carrying out vaccinations, even in countries where this was previously unprecedented.